Epidemic features and megagenomic analysis of childhood Mycoplasma pneumoniae post COVID-19 pandemic: a 6-year study in southern China

References

• Atkinson TP, Balish MF, Waites KB. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections: figure 1. FEMS Microbiol Rev. 2008;32(6):956–973. doi:10.1111/j.1574-6976.2008.00129.x
   PubMed Web of Science ®Google Scholar
• Vervloet LA, Marguet C, Camargos PAM. Infection by Mycoplasma pneumoniae and its importance as an etiological agent in childhood community-acquired pneumonias. Braz J Infect Dis. 2007;11(5):507–514. doi:10.1590/S1413-86702007000500012
   PubMed Web of Science ®Google Scholar
• Sauteur PMM, Beeton ML, Pereyre S, et al. Mycoplasma pneumoniae: delayed re-emergence after COVID-19 pandemic restrictions. The Lancet Microbe. 2023;5(2):e100–e101. doi:10.1016/S2666-5247(23)00344-0
   Google Scholar
• Cullinan M. Child pneumonia cases emerge in Europe as China battles wave of respiratory illness. The telegraph. 2023. https://www.telegraph.co.uk/global-health/science-and-disease/child-pneumonia-europe-france-ireland-denmark-netherlands/
   Google Scholar
• Statens Serum Institut (Danish disease agency). Increased occurrence of Mycoplasma pneumoniae. 2023. https://en.ssi.dk/news/epi-news/2023/no-35—2023
   Google Scholar
• WHO. Upsurge of respiratory illnesses among children-Northern China. 2023. https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON494
   Google Scholar
• WHO. WHO statement on reported clusters of respiratory illness in children in Northern China. 2023. https://www.who.int/news/item/22-11-2023-who-statement-on-reported-clusters-of-respiratory-illness-in-children-in-northern-china
   Google Scholar
• Chen B, Wang M, Huang X, et al. Changes in incidence of notifiable infectious diseases in China under the prevention and control measures of COVID-19. Front Public Health. 2021;9:12. doi:10.3389/fpubh.2021.728768
   Web of Science ®Google Scholar
• Wang L, Guo X, Zhao N, et al. Effects of the enhanced public health intervention during the COVID-19 epidemic on respiratory and gastrointestinal infectious diseases in China. J Med Virol. 2022;94(5):2201–2211. doi:10.1002/jmv.27619
   PubMed Web of Science ®Google Scholar
• Soo RJJ, Chiew CJ, Ma S, et al. Decreased influenza incidence under COVID-19 control measures, Singapore. Emerg Infect Dis. 2020;26(8):1933–1935. doi:10.3201/eid2608.201229
   PubMed Web of Science ®Google Scholar
• Feng L, Zhang T, Wang Q, et al. Impact of COVID-19 outbreaks and interventions on influenza in China and the United States. Nat Commun. 2021;12(1):3249. doi:10.1038/s41467-021-23440-1
   PubMed Web of Science ®Google Scholar
• Zhang Y, Huang Y, Ai T, et al. Effect of COVID-19 on childhood Mycoplasma pneumoniae infection in Chengdu, China. BMC Pediatr. 2021;21(1):6. doi:10.1186/s12887-021-02679-z
   PubMedGoogle Scholar
• Xu M, Liu P, Su L, et al. Comparison of respiratory pathogens in children with lower respiratory tract infections before and during the COVID-19 pandemic in Shanghai, China. Front Pediatr. 2022;10:8. doi:10.3389/fped.2022.881224
   Web of Science ®Google Scholar
• Chen J, Zhang J, Lu Z, et al. Mycoplasma pneumoniae among Chinese outpatient children with mild respiratory tract infections during the coronavirus disease 2019 pandemic. Microbiol Spectr. 2022;10(1):11. doi:10.1128/spectrum.01550-21
   Web of Science ®Google Scholar
• The National Health Commission of the People’s Republic of China. Prevention and control strategy of 2019-novel coronavirus (version 9). 2022. [cited 2022 Dec 23]. http://chrome-extension://ibllepbpahcoppkjjllbabhnigcbffpi/http://www.gov.cn/xinwen/2022-06/28/5698168/files/9585944023424f45a4b4d522b5f5c034.pdf
   Google Scholar
• Group CMAPBR, Board CJoPPE. Expert consensus on the diagnosis and treatment of Mycoplasma pneumoniae pneumonia in children (2015 version). Chin J Pract Pediatr. 2015;30(17):1304–1308.
   Google Scholar
• Group NHCCECoRDUPDUP. Chinese expert consensus on laboratory diagnosis standard and clinical practice for Mycoplasma pneumoniae infection in children (2019 version). Chin J Pediatr. 2020;58(5):366–373.
   Google Scholar
• Huang L, Yang C, Pan H, et al. Effects of public health interventions and zero COVID policy on paediatric diseases: A Southern China study. J Glob Health. 2024:14:9. doi:10.7189/jogh.14.05011
   Web of Science ®Google Scholar
• Kuitunen I, Artama M, Mäkelä L, et al. Effect of social distancing due to the COVID-19 pandemic on the incidence of viral respiratory tract infections in children in Finland during early 2020. Pediatr Infect Dis J. 2020;39(12):e423–e427. doi:10.1097/INF.0000000000002845
   PubMed Web of Science ®Google Scholar
• Saravanos GL, Hu N, Homaira N, et al. RSV epidemiology in Australia before and during COVID-19. Pediatrics. 2022;149(2):10. doi:10.1542/peds.2021-053537
   Web of Science ®Google Scholar
• Teirlinck AC, Johannesen CK, Broberg EK, et al. New perspectives on respiratory syncytial virus surveillance at the national level: lessons from the COVID-19 pandemic. Eur Respir J. 2023;61(4):7. doi:10.1183/13993003.01569-2022
   Web of Science ®Google Scholar
• Cheng Y, Cheng Y, Dai S, et al. The prevalence of Mycoplasma pneumoniae among children in Beijing before and during the COVID-19 pandemic. Front Cell Infect Microbiol. 2022;12:6. doi:10.3389/fcimb.2022.854505
   Web of Science ®Google Scholar
• Cai F, Shou X, Ye Q. Epidemiological study on Mycoplasma pneumoniae and Chlamydia pneumoniae infection of hospitalized children in a single center during the COVID-19 pandemic. Front Cell Infect Microbiol. 2022;12:8. doi:10.3389/fcimb.2022.843463
   Web of Science ®Google Scholar
• Wang H, Zheng Y, de Jonge MI, et al. Lockdown measures during the COVID-19 pandemic strongly impacted the circulation of respiratory pathogens in Southern China. Sci Rep. 2022;12(1):8. doi:10.1038/s41598-022-21430-x
   PubMed Web of Science ®Google Scholar
• Feng Y, Zhang H, Zhang B, et al. Impact of normalized COVID-19 prevention and control measures on lower respiratory tract infection pathogenesis in hospitalized children. Front Public Health. 2024;12:8. doi:10.3389/fpubh.2024.1367614
   Web of Science ®Google Scholar
• Li L, Wang H, Liu A, et al. Comparison of 11 respiratory pathogens among hospitalized children before and during the COVID-19 epidemic in Shenzhen, China. Virol J. 2021;18(1):6. doi:10.1186/s12985-021-01669-y
   PubMed Web of Science ®Google Scholar
• Zhang LN, Cao L, Meng LH. Pathogenic changes of community-acquired pneumonia in a children’s hospital in Beijing, China before and after COVID-19 onset: a retrospective study. World journal of pediatrics : WJP. 2022;18(11):746–752. doi:10.1007/s12519-022-00592-8
   PubMed Web of Science ®Google Scholar
• Mai W, Ren Y, Tian X, et al. Comparison of common human respiratory pathogens among hospitalized children aged ≤6 years in Hainan Island, China, during spring and early summer in 2019-2021. J Med Virol. 2023;95(4):7. doi:10.1002/jmv.28692
   Web of Science ®Google Scholar
• Zhou D, del Valle-Mendoza J, Orellana-Peralta F, et al. High prevalence of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with acute respiratory infections from Lima, Peru. PLoS One. 2017;12(1):e0170787. doi:10.1128/spectrum.01550-21
   PubMed Web of Science ®Google Scholar
• Ambooken B, Balakrishnan PP, Asokan N, et al. Ulcerated lobular panniculitis: an unusual initial presentation of anti-Mi-2-alpha positive dermatomyositis. Indian J Dermatol Venereol Leprol. 2022;88:381–384. doi:10.25259/IJDVL_848_2021
   PubMed Web of Science ®Google Scholar
• da Silva SJR, Pena L. Collapse of the public health system and the emergence of new variants during the second wave of the COVID-19 pandemic in Brazil. One Health. 2021;13:5. doi:10.1016/j.onehlt.2021.100287
   PubMed Web of Science ®Google Scholar
• Wang A, Wu Z, Huang Y, et al. A 3D-printed microfluidic device for qPCR detection of macrolide-resistant mutations of Mycoplasma pneumoniae. Biosensors. 2021;11(11):427. doi:10.3390/bios11110427
   PubMedGoogle Scholar
• Zhan X-W, Deng L-P, Wang Z-Y, et al. Correlation between Mycoplasma pneumoniae drug resistance and clinical characteristics in bronchoalveolar lavage fluid of children with refractory Mycoplasma pneumoniae pneumonia. Ital J Pediatr. 2022;48(1):19. doi:10.1186/s13052-022-01376-6
   PubMed Web of Science ®Google Scholar
• Li H, Li S, Yang H, et al. Resurgence of Mycoplasma pneumoniae by macrolide-resistant epidemic clones in China. The Lancet Microbe. 2024;1. doi:10.1016/S2666-5247(23)00405-6
   Google Scholar
• Xu M, Li Y, Shi Y, et al. Molecular epidemiology of Mycoplasma pneumoniae pneumonia in children, Wuhan, 2020–2022. BMC Microbiol. 2024;24(1):11. doi:10.1186/s12866-024-03180-0
   PubMed Web of Science ®Google Scholar
• Xing F-F, Chiu KH-Y, Deng C-W, et al. Post-COVID-19 pandemic rebound of macrolide-resistant Mycoplasma pneumoniae infection: a descriptive study. Antibiotics. 2024;13(3):13. doi:10.3390/antibiotics13030262
   Google Scholar